What does the Antinuclear Antibody (ANA) lab test indicate?

Understanding the Antinuclear Antibody (ANA) Test

The Antinuclear Antibody (ANA) test detects autoantibodies directed against various cellular components and serves as a fundamental screening tool for systemic autoimmune rheumatic diseases, particularly systemic lupus erythematosus (SLE). 1, 2

What ANA Tests Detect

ANA tests identify antibodies targeting various cellular components, including:

• Nuclear components: DNA, histones, chromatin
• Nuclear envelope structures
• Cytoplasmic components: ribosomes, tRNA synthetases
• Mitotic spindle apparatus
• Cell membrane components 1

The term "ANA" is actually outdated and somewhat confusing as it now encompasses antibodies directed at various cellular compartments beyond just the nucleus 1.

Testing Methods

Indirect Immunofluorescence Assay (IIFA)

• Considered the gold standard method by the American College of Rheumatology 1, 3
• Uses HEp-2 cells or variants as substrate
• Provides pattern information that can suggest specific autoantibodies
• Requires technical expertise for interpretation
• Typical screening dilution is 1:160 for adults (86.2% specificity, 95.8% sensitivity) 2
• For children, a lower dilution of 1:20 may be used 2

Alternative Methods

• ELISA (Enzyme-Linked Immunosorbent Assay)
• Addressable laser bead immunoassay
• Chemiluminescence immunoassay
• Line immunoassays 1, 3

These newer automated methods may offer higher throughput but can differ in sensitivity and specificity compared to IIFA 3.

Staining Patterns and Clinical Associations

Different staining patterns can suggest specific autoantibodies and associated conditions:

Pattern	Associated Antigens	Associated Conditions
Homogeneous	dsDNA, histones	SLE, drug-induced lupus
Coarse speckled	U1-SnRNP, Sm	MCTD, SLE, Raynaud's
Fine speckled	SSA/Ro, SSB/La	SLE, Sjögren's syndrome
Centromere	CENP proteins	Limited systemic sclerosis
Nucleolar	PM/Scl, RNA-polymerase	Systemic sclerosis
Cytoplasmic diffuse	Ribosomal P, Jo-1	SLE, inflammatory myopathies

1

Clinical Significance and Interpretation

Positive ANA Results

• Sensitivity: High for SLE (95-99%), moderate for other autoimmune diseases
• Specificity: Limited (20-30% of healthy individuals may have positive ANA) 4
• Titer significance:
  • Higher titers (≥1:160) are more likely to be clinically significant 2
  • Lower titers (1:40-1:80) may be seen in healthy individuals 2

Follow-up Testing

• Positive ANA should prompt testing for specific autoantibodies:
  • Anti-dsDNA (specific for SLE)
  • Anti-ENA (extractable nuclear antigens) including:
    • Anti-Sm (specific for SLE)
    • Anti-SSA/Ro (Sjögren's, SLE, neonatal lupus)
    • Anti-SSB/La (Sjögren's, SLE)
    • Anti-RNP (MCTD, SLE)
    • Anti-Jo-1 (inflammatory myopathies) 1, 2

Important Clinical Considerations

When to Order ANA Testing

• Order when clinical symptoms suggest systemic autoimmune disease
• Not recommended as a general screening test without specific clinical suspicion 2

Pitfalls and Caveats

• False positives: Can occur in:
  • Healthy individuals (especially elderly)
  • Acute and chronic infections 5
  • Certain malignancies 6
  • Drug-induced lupus
• False negatives: Some autoantibodies (e.g., anti-Jo-1, anti-ribosomal P) may be present despite negative ANA by IIFA 1

Monitoring Considerations

• ANA testing is primarily for diagnosis, not monitoring disease activity
• For SLE monitoring, quantitative anti-dsDNA antibody testing is preferred 1
• Asymptomatic individuals with isolated low-titer ANA do not require routine monitoring 2

Referral Guidelines

Refer to rheumatology when:

• Positive ANA with specific clinical signs/symptoms of autoimmune disease
• Laboratory abnormalities suggestive of autoimmune disease
• Persistent unexplained symptoms despite negative initial workup 2

Remember that while ANA is an important diagnostic tool, it must be interpreted in the appropriate clinical context, as a positive result alone is insufficient for diagnosis of any autoimmune condition 2, 4.